Trial Profile
A Study to Evaluate the Clinical Characteristics, Treatment Patterns, Safety and Outcomes for Patients With HER2-Positive Metastatic Breast Cancer(mBC) who Received a Pertuzumab-Containing Regimen
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2016
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Docetaxel; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Feb 2016 New trial record
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium